Use access key #2 to skip to page content.
$64.15 0.32 (0.50%)
9/8/2008 11:39 AM

ImClone Systems, Inc. (IMCL)

CAPS Rating:
**

A biopharmaceutical company which advances oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.

View All Commentary (IMCL)

Recs

0

Avatar ebtc (62.81) Submitted: 1/29/07 3:10 PM : Outperform Start Price: $28.72 IMCL Score: 134.46

With earnings out of the way speculators will cover shorts into February's Merrill healthcare conferences - where IMCL appears 6-8th.

Report this Post Replies: 0 | Reply

Featured Broker Partners